Interview: Evgeniy Gaydukov – Country Director, AstraZeneca Ukraine
Evgeniy Gaydukov, Country Director of AstraZeneca Ukraine, provides insights into the remarkable growth that the…
AstraZeneca UK
Last updated: 07.09.2018
Address: London, England W1K 1LN,United Kingdom
Tel: 0207 604 8032
Web: http://www.astrazeneca.co.uk/home/
Company description
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company. In 2013, it moved its headquarters to Cambridge, UK, and concentrated its R&D in three sites: Cambridge; Gaithersburg, Maryland, USA (location of MedImmune) for work on biopharmaceuticals; and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs.[5] AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation.[6]
The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group[7][8] (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). Since the merger it has been among the world’s largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
AstraZeneca has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. It has secondary listings on the New York Stock Exchange and the OMX exchange.
Products and services
Cardivascular medicine
Gastrointestinal medicines
Infection medicines
Oncology medicines
Neuroscience medicines
Respiratory and Inflammation medicines
Interviews
Interview with Mark Jones, Marketing Company President, AstraZeneca UK
AstraZeneca reported decrease in its global revenue for the first half of 2011 mostly due to adverse market…
Related
Europe / Top 5 Pharma R&D Spenders
The Top Five countries in Europe ranked by amount spent on pharma R&D. While some of the continent’s largest…
Global / Is Everything So Wrong at GSK?
British pharmaceuticals giant, GSK, one of the UK’s largest companies by market capitalization, is once again…
Global / PharmaBoardroom's Top 5 Op-Eds in 2021 (So Far)
As our thoughts here at PharmaBoardroom turn towards the summer holidays, we are happy to share the five most-read…
Kathy Pritchard-Jones – President, International Society of Paediatric…
Kathy Pritchard-Jones, Professor of Paediatric Oncology at University College London (UCL) and President of the…
Zack Pemberton-Whiteley – CEO, Leukaemia Care
Zack Pemberton-Whiteley, CEO of UK-based blood cancer charity Leukaemia Care, discusses the importance of patient…
Europe / Vaccine Wars: What the EU/AstraZeneca Row Shows Us About Pharma Cross-Border Litigation
Stuart Evans, partner at law firm BLM and specialist in commercial disputes and litigation examines the origins and…
UK / Fastest Growing Private Pharmacos; GSK Shake-Up; Brexit Uncertainties; COVID-19 Reinfection Trial
The latest UK pharma news, including how new investment in GSK stands to reshape the country’s iconic pharma…
M&A / Jazz’s $7.2 Billion GW Pharma Deal: A Major Boost for Cannabinoid Research
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical…
MEA / Pfizer’s Saudi Transformation; Urgent Call for Arab Import Reform; Hikma & Tabuk Deals
The latest news from Middle East & North African pharma, including Pfizer’s transformation of its Saudi…
Europe / After Brexit: Focus on the New Pharmaceutical Strategy for Europe
Writing in the February edition of DIA’s Global Forum magazine, Thomas Kühler of Sanofi R&D looks at the…
Saudi Arabia / 5 Pharma Companies to Know
Following on from our list of the overall top 10 companies in the Saudi Arabian pharma market, here PharmaBoardroom…
Japan / Taiho Pharmaceutical: An Oral Chemotherapy Pioneer
Japanese pharma companies are already far lower-profile than their occidental counterparts but an even lesser-known…
